Curious to see your top suppliers emissions?
Book a demo for a pilot project
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparation ManufacturingUnited States
Last verified 18 days agomatinasbiopharma.com
Matinas BioPharma Holdings, Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 2013, the company has made significant strides in developing innovative lipid-based drug delivery systems, particularly for the treatment of infectious diseases and other serious health conditions.
Matinas BioPharma is renowned for its unique core product, the MAT9001, which leverages its proprietary lipid nanocrystal technology to enhance the bioavailability of therapeutic agents. This innovative approach positions the company at the forefront of the pharmaceutical sector, addressing critical needs in drug delivery.
With a commitment to advancing healthcare solutions, Matinas BioPharma has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its market position as a leader in pharmaceutical innovation.
23
DitchCarbon score
-17 vs industry average
Matinas BioPharma Holdings, Inc.’s score of 23 is lower than 36% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Matinas BioPharma Holdings, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Matinas BioPharma Holdings, Inc.'s reported carbon emissions
Matinas BioPharma Holdings, Inc., a US-based pharmaceutical preparation manufacturing company, reported its 2022 Scope 1 emissions as approximately 404,000 kg CO2e and Scope 2 emissions as approximately 282,600 kg CO2e. In 2021, the company reported Scope 1 emissions of approximately 533,000,000 kg CO2e. The company has not publicly disclosed any Scope 3 emissions data. Matinas BioPharma Holdings, Inc. has not set any specific carbon reduction targets or made climate commitments such as Science Based Targets initiative (SBTi) targets or a Climate Pledge.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Matinas BioPharma Holdings, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Matinas BioPharma Holdings, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Matinas BioPharma Holdings, Inc.18 days ago
23
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more